Neuropathic pain is pain arising from a lesion or disease affecting the somatosensory nervous system — the peripheral nerves, spinal cord, or brain. Unlike nociceptive pain (the normal protective pain response to tissue damage), neuropathic pain involves pathological changes in pain processing — abnormal neuronal excitability, sensitisation, and ectopic discharge. Clinically, neuropathic pain is characterised by distinctive sensory features: burning, shooting, or electric-shock-like pain; allodynia (pain from normally non-painful stimuli, such as light touch or clothing contact); hyperalgesia (exaggerated pain response to normally mild stimuli); and spontaneous pain occurring without any stimulus.
Common conditions producing neuropathic pain include: postherpetic neuralgia (PHN — pain persisting after shingles), diabetic peripheral neuropathy (DPN — the most common complication of long-standing diabetes), trigeminal neuralgia, central post-stroke pain, complex regional pain syndrome (CRPS), chemotherapy-induced peripheral neuropathy (CIPN), and pain associated with multiple sclerosis. Neuropathic pain is notoriously undertreated and responds poorly to standard analgesics (NSAIDs, acetaminophen, weak opioids) — its treatment requires specific pharmacological agents targeting the altered neurophysiology of neuropathic pain states.
The gabapentinoid drug class — calcium channel alpha-2-delta subunit ligands — represents the pharmacological backbone of neuropathic pain management. Gabapentin (Neurontin) and pregabalin (Lyrica) are the two principal gabapentinoids with robust evidence in multiple neuropathic pain conditions. They modulate voltage-gated calcium channels by binding to the alpha-2-delta subunit, reducing neuronal calcium influx and thereby decreasing the release of excitatory neurotransmitters (glutamate, substance P, norepinephrine) at hyperexcitable synapses. Other pharmacological options include tricyclic antidepressants (amitriptyline, nortriptyline — often first-line in diabetic neuropathy), SNRIs (duloxetine — FDA-approved for DPN and fibromyalgia), and topical agents (lidocaine patches, capsaicin 8% patch for PHN). Opioids and tramadol have limited, specialist-supervised roles in refractory neuropathic pain.
Lucas Clinic provides detailed information about the gabapentinoid nerve pain medications in our inventory: